dsm-firmenich has teamed up with biotechnology company Inscripta to develop "a novel, highly sought-after well-aging skin care ingredient," as well as other sustainable biotech-based ingredient innovations.
Inscripta's GenoScaler platform, described as "a complete, end-to-end, solution for rapid microbial optimization for industrial biomanufacturing," taps into whole genome engineering to quickly scale up specialty ingredients.
The partnership comes amid a boom in biotech-driven beauty.
“Our deep expertise in biotechnology is a key driver of innovation, enabling us to deliver new-to-the-world ingredients, improve our existing solutions, and provide a consistent supply to our businesses,” said Sarah Reisinger, chief science and research officer at dsm-firmenich. “Biotechnology is also helping us make our solutions more sustainable, supporting important moves towards eco-conscious beauty. We are excited about the new possibilities we can unlock by combining Inscripta’s cutting-edge biotech tools and expertise with our own.”
“As leaders in biotechnology, at dsm-firmenich we are thrilled to collaborate with Inscripta, a well-respected innovator in biotech strain engineering,” said Parand Salmassinia, president of beauty and care at dsm-firmenich. “By integrating Inscripta’s scientific knowledge with our biotechnology skincare expertise, we’re set to deliver next-generation well-aging products that offer superior results while contributing to a more sustainable future. Our biotech leadership will ensure that we not only meet consumer expectations but exceed them”.
“Partnering with dsm-firmenich allows us to demonstrate the full potential of biotechnology in the beauty industry,” said Sri Kosaraju, president and CEO at Inscripta. “Our GenoScaler platform, combined with dsm-firmenich’s vast experience in biotech, presents new opportunities for creating bio-active ingredients that meet the high-performance standards of today’s skincare market, while also addressing the growing demand for sustainability.”
